Table 4.
Comparison between lung cancer patients admitted in 2019 and 2020
| Variables | Patients 2019 (N=36) | Patients 2020 (N=46) | P |
|---|---|---|---|
| Age at LC diagnosis, median (IQR), years | 65.0 (54.8–71.8) | 66.5 (59.8–71.0) | 0.712* |
| Gender, n (%) | 0.269** | ||
| Male | 26 (72) | 34 (74) | |
| Female | 10 (28) | 12 (26) | |
| Smoking history, n (%) | 0.584** | ||
| Yes | 28 (78) | 38 (83) | |
| No | 8 (22) | 8 (17) | |
| Histology, n (%) | 0.057** | ||
| NSCLC | 34 (94) | 37 (80) | |
| SCLC | 2 (6) | 9 (20) | |
| OE as presentation of lung cancer, n (%) | 16 (44) | 21 (46) | 0.913** |
| Time between diagnosis and OE, median (IQR), months | 1.0 (0.1–8.3) | 1.5 (0.1–10.3) | 0.670* |
| Stage, n (%) | 0.276** | ||
| Metastatic | 29 (81) | 41 (89) | |
| Non-metastatic | 7 (19) | 5 (11) | |
| Type of oncologic emergency, n (%) | 0.733** | ||
| Neurologic | 18 (50) | 25 (54) | |
| Respiratory | 5 (14) | 8 (17) | |
| Cardiovascular | 13 (36) | 13 (28) | |
| Mortality at 6 months (alive), n (%) | 9 (25) | 13 (28) | 0.741** |
Abbreviations: IQR: interquartile range; OE, oncologic emergency; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer
* T-test;
** Chi-square test